Insurance companies are not quietly driving the growth of mass tort lawsuits—they’re actually fighting against it. While the title suggests insurers orchestrate litigation expansion, the verified data reveals a different story: the real engine behind exploding mass tort filings is third-party litigation funding (TPLF), a $15+ billion industry that’s grown nearly 20% in just two years. Insurance companies have become vocal opponents of this litigation funding boom, escalating their resistance throughout 2025 and into 2026 with lobbying efforts, regulatory pushes, and public opposition. Understanding what’s actually happening requires looking past the surface narrative to the financial incentives that truly fuel mass tort growth.
The numbers tell the compelling story. As of March 2026, there are approximately 199,000 pending cases in multi-district litigations (MDLs), with over 704,000 total cases filed across the system. The Johnson & Johnson talcum powder litigation alone involves 67,100 pending cases, while hernia mesh cases account for 24,000 and AFFF firefighting foam litigation spans 15,200 cases. These are real people with real injuries, but the question of who’s orchestrating this growth matters for understanding how the system actually works. It’s not insurance company strategy—it’s outside money betting on litigation outcomes.
Table of Contents
- Who Is Actually Funding Mass Torts—And Why It’s Not Insurance Companies
- The Third-Party Litigation Funding Industry—How It Fuels Mass Torts
- Insurance Industry Costs and the Rise of “Nuclear Verdicts”
- Real-World Examples of How Litigation Funding Changes Case Dynamics
- How Settlement Negotiations Change When Outside Money Is Involved
- Regulatory Responses and Litigation Funding Disclosure Requirements
- The Future of Litigation Funding and What It Means for Mass Torts
- Conclusion
- Frequently Asked Questions
Who Is Actually Funding Mass Torts—And Why It’s Not Insurance Companies
Third-party litigation funding firms have become the silent architects of mass tort expansion. These specialized financiers provide capital to law firms and individual claimants, betting that settlements or verdicts will generate returns far exceeding their investment. The industry didn’t emerge by accident: it grew explosively because litigation is expensive, and attorneys often cannot afford to bankroll complex cases involving thousands of plaintiffs. A litigation funder steps in, covers legal costs, and in return receives 20-50% of attorney fees or settlement proceeds—essentially purchasing a financial stake in the lawsuit’s outcome. insurance companies, by contrast, are the targets paying these settlements. They face the opposite incentive: they want fewer lawsuits, smaller payouts, and less litigation activity.
In 2025, insurance industry organizations became explicitly vocal opponents of litigation funding, recognizing that when outside money removes barriers to filing cases, claim volumes and settlement amounts both increase. The American Insurance Association and other industry groups began publishing reports linking TPLF to rising insurance costs and warning that litigation funding accelerates cases that might otherwise settle faster or for less money. The distinction matters for everyone filing claims. When a litigation funder finances your case, it’s not charity—it’s a business transaction where the funder’s interests may not perfectly align with yours. They profit from higher settlements but also from prolonged litigation. Insurance companies, meanwhile, face an asymmetrical problem: they’re paying the bills whether or not TPLF exists, making them natural opponents of anything that increases litigation velocity or claim values.
The Third-Party Litigation Funding Industry—How It Fuels Mass Torts
The litigation funding industry is projected to grow from $15 billion in 2025 to $31 billion by 2028—a doubling in just three years. This explosive growth reflects the sector’s fundamental business model: identify high-probability litigation, fund it, and capture a share of the proceeds. Funders charge interest rates ranging from 15-40% annually on the capital they advance, meaning that for every dollar borrowed, claimants and attorneys owe significantly more if the case takes longer to resolve. This creates a complex incentive structure where speed, settlement amount, and case complexity all affect profitability. A critical limitation of litigation funding is that it doesn’t eliminate risk—it redistributes it. When a funder finances a case, they’re making a calculated gamble. If the case loses, the claimant owes nothing back, but the litigation funder loses its entire investment.
This risk-bearing can be valuable: it allows cases to proceed that might otherwise die due to lack of funds. But it also means funders actively select cases they believe will win big, potentially skewing which claims get pursued. A plaintiff with a moderate-value claim but limited resources might struggle to secure funding, while a high-value claim with visible damages gets fast-tracked. This creates a hidden gatekeeping function where litigation funders, not courts or regulators, determine which cases proceed. The mechanics of TPLF profoundly affect settlement negotiation. Insurance adjusters know that litigations with outside funding are more likely to proceed to trial because the funder has a financial interest in pursuing maximum recovery. A self-funded plaintiff or attorney might accept a $200,000 settlement offer to conserve resources and move on; a litigation funder might push for trial to target a $500,000 verdict. Insurance companies predictably resist this dynamic, leading to higher claims costs and more contentious litigation.
Insurance Industry Costs and the Rise of “Nuclear Verdicts”
The tort system’s overall costs are growing at roughly 6% annually—a rate that significantly outpaces inflation and GDP growth. Insurance companies attribute much of this acceleration to the combination of third-party litigation funding, attorney advertising, and increasingly plaintiff-friendly legal environments that support “nuclear verdicts”—surprise awards in the tens of millions. A nuclear verdict in one case then becomes a benchmark that influences settlement negotiations in hundreds of similar claims, creating cascading cost increases across the entire system. Insurance companies view third-party litigation funding as the accelerant that makes this problem worse. Before TPLF became mainstream, many mass tort cases settled earlier because attorneys lacked the capital to sustain multi-year litigation. Funders removed this natural brake.
The Insurance Information Institute released a 2025 brief explicitly linking attorney advertising, mass torts, litigation funding, and rising insurance costs—presenting them as an interconnected system driving up premiums for consumers. This perspective, while self-interested, reflects a genuine dynamic: when outside capital removes resource constraints on pursuing litigation, claim volumes and settlement averages both increase, ultimately flowing into higher insurance costs. Insurance industry opposition in 2025 manifested in concrete regulatory pushes. Multiple states—including Arizona, Colorado, Kansas, Georgia, Montana, Oklahoma, and Tennessee—adopted new litigation funding disclosure requirements, mandating that parties reveal when third-party funders are backing a case. These regulations aim to increase transparency but also signal insurance industry success in shaping policy around TPLF. More states are expected to follow, potentially constraining the litigation funding industry’s ability to operate without disclosure, though the industry itself has generally welcomed moderate transparency requirements as preferable to outright bans.
Real-World Examples of How Litigation Funding Changes Case Dynamics
The Johnson & Johnson talcum powder litigation provides a textbook example of how funding and litigation dynamics interact. With 67,100 cases pending, the scope of this litigation would be impossible without significant capital backing. Early claimants faced a choice: settle individually for limited amounts or wait for a coordinated resolution through the MDL process. Litigation funders enabled law firms to maintain thousands of cases simultaneously, aggregating them into collective leverage against a wealthy defendant. Without TPLF, many individual claimants would have settled early for smaller amounts; with it, they could hold out for collective settlement or trial leverage. The hernia mesh litigation, involving approximately 24,000 cases, similarly demonstrates TPLF mechanics. Defective hernia mesh products caused revision surgeries, ongoing pain, and significant damages. The medical complexity required extensive expert testimony, discovery, and trial preparation—all expensive activities.
Litigation funders financed the infrastructure needed to pursue these cases simultaneously across multiple jurisdictions. Defendants faced either settlement to reduce litigation risk or trial against law firms with effectively unlimited resources. Many insurance-backed defendants opted for settlements, but the amounts reflected the litigation funding dynamics: higher than they might have been if attorneys faced resource constraints. A limitation here: litigation funding isn’t inherently bad for claimants. It enables access to justice for people with real injuries who lack personal wealth. A construction worker with a legitimate asbestos-related illness can pursue a claim that might otherwise be economically infeasible. The tension is that TPLF also creates incentives for aggressive case selection, overfunding of borderline claims, and strategic litigation that may not be in individual claimants’ best interests. Funders profit regardless of whether a settlement reaches $100,000 or $300,000; they benefit more from the latter, creating pressure to hold out.
How Settlement Negotiations Change When Outside Money Is Involved
Litigation funding introduces a new party into settlement negotiations: the funder. When an attorney considers a settlement offer, they’re no longer making a solo decision. The litigation funder, having invested capital and charged interest, has contractual rights to approve settlements. This can create misaligned incentives. An attorney might believe a $250,000 settlement is reasonable and want to resolve the case; the funder, seeing higher settlement prospects, might block it and push for continued litigation. Individual claimants can find themselves caught between their attorney’s judgment and their funder’s financial interests. A key warning: litigation funding agreements are complex legal documents with terms that can significantly disadvantage claimants. Some funders retain broad veto rights over settlements, meaning claimants cannot accept an offer they prefer if the funder disagrees.
Interest rates, while disclosed, can compound dramatically on cases lasting years. A claimant funded at 20% annual interest on a case lasting four years finds their debt growing substantially. When the case settles for $300,000, the funder’s take (which can include interest plus a percentage of proceeds) might reach $80,000-$100,000, reducing the claimant’s net recovery. Claimants should understand these mechanics before accepting funding. Insurance companies and defendants understand these dynamics intimately. Their settlement strategies increasingly account for TPLF. They may offer settlement amounts sufficient to cover anticipated funder fees, effectively getting cooperation from the funder by making the deal attractive from everyone’s financial perspective. Or they may pursue aggressive defense tactics designed to increase litigation costs for the funder, making the original investment thesis less attractive and increasing pressure to settle. The presence of litigation funding doesn’t simplify settlement—it adds a new layer of negotiation complexity.
Regulatory Responses and Litigation Funding Disclosure Requirements
The rapid growth of TPLF prompted regulatory attention in 2025. Seven states adopted new disclosure requirements, mandating that parties reveal when litigation funding is involved. Arizona, Colorado, Kansas, Georgia, Montana, Oklahoma, and Tennessee all implemented rules requiring disclosure of funding agreements, funder identities, and key financial terms. These regulations stem from concerns about conflicts of interest, transparency, and the potential for outside money to distort litigation decisions.
Litigation funding industry participants have surprisingly accepted these disclosure requirements, with some actively supporting them. Transparency is less damaging to the industry than outright prohibition, and disclosing funder involvement actually protects the practice by incorporating it into the legal system explicitly. The real regulatory risk for the TPLF industry isn’t disclosure—it’s interest rate caps, approval requirements, or restrictions on certain funder rights. Expect more states to adopt disclosure rules in 2026, with possible movement toward regulating funder conduct or limiting funder veto rights over settlements.
The Future of Litigation Funding and What It Means for Mass Torts
Litigation funding will almost certainly continue growing as an industry. The economic fundamentals support it: cases are expensive, plaintiffs need capital, and outside investors see attractive risk-adjusted returns in proven litigation areas like talcum powder, hernia mesh, and contamination claims. Even with regulatory friction, the industry is projected to reach $31 billion by 2028. Insurance companies will simultaneously escalate their opposition through lobbying, regulatory advocacy, and policy proposals limiting TPLF practices.
The competitive dynamic emerging is clear: litigation funders and insurance companies are in an arms race. Funders develop new strategies to identify winning cases and navigate regulatory constraints; insurers develop new defenses, settlement strategies, and political strategies to limit TPLF influence. Meanwhile, claimants are navigating these complex waters without always understanding the incentive structures affecting their cases. As this sector matures, expect greater attention to funder transparency, standardized disclosure forms, and potentially legislative limits on funder rights or interest rates. The mass tort system is evolving not because insurance companies are secretly orchestrating growth, but because outside capital has fundamentally altered litigation economics.
Conclusion
The premise that insurance companies quietly drive mass tort growth is backwards. Insurance companies are paying the bills for mass torts while actively opposing their expansion. The real engine of litigation growth is third-party litigation funding, a $15+ billion industry projected to reach $31 billion by 2028. Litigation funders provide capital to attorneys and claimants, taking a share of proceeds and creating financial incentives that can accelerate litigation, increase settlement demands, and extend case duration. Insurance companies have recognized this dynamic and are escalating resistance through regulatory advocacy, disclosure requirements, and public opposition.
For claimants considering joining mass torts or accepting litigation funding, understanding these dynamics is essential. TPLF can provide crucial access to justice, enabling cases that would otherwise be impossible. But it also introduces conflicts of interest, complex fee structures, and outside parties who profit regardless of how much you recover. The most important step is entering any litigation with clear-eyed understanding of who benefits from different outcomes and at what cost to you. The next steps include reading litigation funding agreements carefully, discussing terms with independent counsel if possible, and understanding that while your attorney is your advocate, a litigation funder is a financial investor whose interests may diverge from yours.
Frequently Asked Questions
Are litigation funders the same as lawsuit lenders?
Not exactly. Lawsuit lenders typically provide small cash advances to claimants awaiting settlement and charge interest on those advances. Litigation funders are larger financial firms that back entire cases, covering attorney fees, expert costs, and other litigation expenses in return for a percentage of recovery. Litigation funders have greater leverage and more involved roles in case strategy.
Can I refuse a settlement offer my litigation funder rejects?
That depends on your funding agreement. Some agreements give funders veto rights over settlements; others are advisory. You should review your agreement carefully and understand whether the funder has contractual authority to block your desired settlement. If they do, you have limited ability to accept a settlement they reject.
How much of my settlement goes to the litigation funder?
This varies by agreement but typically ranges from 20-50% of attorney fees or total settlement proceeds. If your agreement includes interest at 20% annually and your case lasts three years, your debt to the funder grows substantially. A $300,000 settlement might result in $80,000-$100,000 going to the funder, leaving you with $200,000-$220,000.
Why are insurance companies opposing litigation funding if they’re paying settlements anyway?
Insurance companies are opposing litigation funding because outside capital removes negotiating leverage they previously held. Without funders, many cases settle faster or for less money because attorneys lack resources to sustain litigation. With funders, cases proceed to trial more often and settle for higher amounts. Insurance companies are trying to limit TPLF to reduce their claims costs.
Which states have regulated litigation funding?
As of 2026, Arizona, Colorado, Kansas, Georgia, Montana, Oklahoma, and Tennessee have adopted disclosure requirements for litigation funding. More states are expected to follow. Check with your state’s bar association or a local attorney for current regulations in your jurisdiction.
Does litigation funding make my case stronger or weaker?
Litigation funding provides resources that can strengthen your case by enabling thorough discovery, expert testimony, and litigation infrastructure. However, it also introduces a funder with financial interests that may not perfectly align with yours. The quality of your case depends on the underlying facts and the attorney’s skill; funding provides the resources to develop those facts fully.